SBIR/STTR Research Award
Stable Glucagon for Treatment of Hyperinsulinism
Award amount
$338,388Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AMIDEBIO, LLC
- Proposal award date
- 2017-09-18
- Contract end date
- 2019-08-31
- UEI
- UN9KNR7J6J77
- Solicitation number
- PA16-302
- Topic code
- 200
Research abstract
SUMMARY ABSTRACT
A series of glucagon analogues will be designedproduced at milligram levelstested for solution stability and
both in vitro and in vivo activity with the goal of providing a long term treatment for hyperinsulinism
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)
- Long-acting Stable Glucagons for Treatment of Hyperinsulinism
- Novel Glucose Responsive Insulin for Improved Treatment of Diabetes
- Stable Glucagon for Treatment of Hyperinsulinism
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment
Research funding history
5 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $6,817,932. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services